Here are five points:
1. Zacks has a $20 price objective on K2M’s stock.
2. The firm also estimates a potential upside of 11.11 percent.
3. With a 50-day moving average of $16.82, K2M has a 200-day moving average of $15.37.
4. The company’s market capitalization is $758.61 million.
5. K2M’s 52-week low is $10.10 and its 52-week high is $21.67.
More articles on devices:
Fortimedix Surgical receives CE Mark approval for FMX314: 3 notes
ChoiceSpine names new vice president of biologics: 4 key notes
Zacks lowers Orthofix to ‘hold’ rating — 5 quick facts
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
